The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity

International Journal of Tuberculosis and Lung Disease

Volumn 8, Issue 12, 2004, Pages 1499-1505

  Fernández Villar, Alberto ^a,c   Sopena B ^a   Fernandez Villar J ^a   Vazquez Gallardo R ^a   Ulloa, F ^b   Leiro, V ^a   Mosteiro, M ^a   Pineiro L ^a  

^a Xeral Cies University Hospital   (Spain)

^b Nicolas Pena Hospital   (Spain)

^c NONE   (Spain)

Author keywords

Anti tuberculosis drugs; Risk factors; Severe hepatotoxicity

Indexed keywords

ACENOCOUMAROL; ALANINE AMINOTRANSFERASE; AMOXICILLIN PLUS CLAVULANIC ACID; CYCLOSERINE; DICLOFENAC; DIGOXIN; ENALAPRIL; ETHAMBUTOL; FUROSEMIDE; IBUPROFEN; ISONIAZID; LEVOFLOXACIN; MEVINOLIN; OMEPRAZOLE; PARACETAMOL; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADULT; AGE; AGED; ALCOHOL ABUSE; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ABUSE; FEMALE; FOLLOW UP; HEPATITIS; HUMAN; INCIDENCE; LIVER TOXICITY; MALE; MALNUTRITION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; COHORT STUDIES; FEMALE; HEPATITIS, TOXIC; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 11244337479     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. American Thoracic Society, Centres for Disease Control and Prevention and Infectious Diseases Society of America: Treatment of Tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
2. Vidal R, Rey R, Espinar A, et al. Treatment and retreatment of tuberculosis. Arch Bronconeumol 1996; 32: 463-474.
3. Caminero Luna J A. Tratamiento de la tuberculosis. Guía de la Tuberculosis para Médicos Especialistas. París, Francia: Unión Internacional Contra la tuberculosis y Enfermedades Respiratorias, 2003: pp 156-192.
4. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167: 1472-1477.
5. Steele M, Burk R F, DesPrez R M. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99: 465-471.
6. Thompson N P, Caplin M E, Hamilton M I, et al. Anti-tuberculosis medication and the liver: dangers and recommendations in management. Eur Respir J 1995; 8: 1384-1388.
7. Vidal Pla R, de Gracia X, Gallego B, Algueró C, Bravo C. The hepatotoxicity of tuberculosis treatment. Med Clin (Barc) 1991; 97: 481-485.
8. Teleman M D, Chee CB, Earnest A, Wang Y T. Hepatotoxicity of tuberculosis chemotherapy under general program conditions in Singapore. Int J Tuberc Lung Dis 2000; 6: 699-705.
9. Sharma S K, Balamurugan A, Saha P K, Pandey R M, Mehra N K. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002; 166: 916-919.
10. Pande J N, Singh S P, Khilnani G C, Khilnani S, Tandon R K. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996; 51: 132-136.
11. Huang Y S, Chern H D, Su W J, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35: 883-889.
12. Ungo J, Jones D, Ashkin D, et al. A. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157: 1871-1876.
13. Wong W M, Wu P C, Yuen M F, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000; 3: 201-206.
14. Fernández-Villar A, Sopeña B, Vázquez R, et al. Isoniazid hepatotoxicity among drug users. The role of hepatitis C. Clin Infect Dis 2003; 36: 293-298.
15. Kopanoff D E, Snider D E Jr, Caras G J. Isoniazid-related hepatitis: a US Public Health Service co-operative surveillance study. Am Rev Respir Dis 1978; 117: 991-1001.
16. Devoto F M, Gonzalez C, Iannantuono R, Serra H A, Gonzalez C D, Saenz C. Risk factors for hepatotoxicity induced by anti-tuberculosis drugs. Acta Physiol Pharmacol Ther Latinoam 1997; 47: 197-202.
17. Gilroy S A, Rogers M A, Blair D C. Treatment of latent tuberculosis infection in patients aged >35 years. Clin Infect Dis 2000; 31: 826-829.
18. Singh J, Arora A, Garg P K, Thakur V S, Pande J N, Tandon R K. Antituberculosis treatment-induced hepatotoxicity: role of predictive factors. Postgrad Med J 1995; 71: 359-362.
19. Larrey D. Drug-induced liver diseases. J Hepatol 2000; 32 (Suppl 1): 77-88.
20. Nolan C M, Sandblom R E, Thummel K E, Slaterry J T, Nelson S D. Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. Chest 1994; 105: 408-411.
21. Huang Y S, Chern H D, Su W J, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37: 924-930.
22. Nguyen M H, Garcia G. Does isoniazid cause more serious hepatotoxicity in hepatitis B virus carriers? Am J Gastroenterol 2002; 97: 1092-1093.
23. World Health Organization. Alcohol training in general practice. EUR/ICP/ADA 038 (B). Copenhagen, Denmark: WHO, 1994.
24. World Health Organization. ART Adverse Drug Reaction Terminology. Geneva, Switzerland: WHO Collaborating Centre for Drug International Monitoring, 1979.
25. Nolan C M, Goldberg S V, Buskin S E. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281: 1014-1018.
26. Joint Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53: 536-548.
27. Durand F, Bernuau J, Pessayre D, et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology 1995; 21: 929-932.
28. Mitchell I, Wendon J, Fitt S, Williams R. Antituberculosis therapy and acute liver failure. Lancet 1995; 345: 555-556.
29. Schenker S, Martin R R, Hoyumpa A. Antecedent liver disease and drug toxicity. J Hepatol 1999; 31: 1098-1105.